Skip to main content
Top

25-04-2024 | Finerenone | Nephrology – Original Paper

Intellectual landscapes and emerging trends of non-steroidal mineralocorticoid receptor antagonists: a bibliometric and visual analysis

Authors: Lili Zhu, Ping Shi

Published in: International Urology and Nephrology

Login to get access

Abstract

Purpose

With increasing studies, non-steroidal mineralocorticoid receptor (MR) antagonists have been increasingly recognized as a major novel dimension in cardiorenal disease therapy. This bibliometric analysis aimed to uncover current research status and identify future research directions in the study of non-steroidal MR antagonists to inform subsequent investigations.

Methods

Relevant English-language literature was retrieved from the Science Citation Index Expanded of the Web of Science Core Collection on January 10, 2024. Analyses of countries, institutions, authors, journals, documents, cited references and keywords were performed by the CiteSpace and VOSviewer software.

Results

Overall, 498 documents, including 297 articles and 201 reviews, were included and analyzed. The United States (n = 188), Bayer AG (n = 78), and Professor Peter Kolkhof (n = 59) were the most prolific country, institution, and author in this field, respectively. Cluster analysis of cited references identified major clusters like cardiovascular disease, chronic kidney disease, and omecamtiv mecarbil. Keyword analysis indicated that sodium–glucose transport protein (SGLT)-2 inhibitors, pharmacotherapy, clinical trial, and guideline have emerged recently.

Conclusion

The field of non-steroidal MR antagonists is gradually gaining momentum as a novel pharmacotherapy in cardiorenal diseases, especially diabetic kidney disease, hypertension, and heart failure. Future studies will focus on add-on pharmacotherapy by combining non-steroidal MR antagonists with SGLT-2 inhibitors and the development and publication of clinical guidelines to facilitate patient management.
Appendix
Available only for authorised users
Literature
17.
18.
go back to reference ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2024 April 24. Identifier NCT05047263, A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Nondiabetic Chronic Kidney Disease (FIND-CKD). https://clinicaltrials.gov/study/NCT05047263 ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2024 April 24. Identifier NCT05047263, A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Nondiabetic Chronic Kidney Disease (FIND-CKD). https://​clinicaltrials.​gov/​study/​NCT05047263
21.
go back to reference ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2024 April 24. Identifier NCT04435626, Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF). https://classic.clinicaltrials.gov/ct2/show/NCT04435626 ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2024 April 24. Identifier NCT04435626, Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF). https://​classic.​clinicaltrials.​gov/​ct2/​show/​NCT04435626
35.
go back to reference Giugliano D, Maiorino MI, Bellastella G, Longo M, Chiodini P, Esposito K (2019) GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis including the REWIND and PIONEER 6 trials. Diabetes Obes Metab 21(11):2576–2580. https://doi.org/10.1111/dom.13847CrossRefPubMed Giugliano D, Maiorino MI, Bellastella G, Longo M, Chiodini P, Esposito K (2019) GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis including the REWIND and PIONEER 6 trials. Diabetes Obes Metab 21(11):2576–2580. https://​doi.​org/​10.​1111/​dom.​13847CrossRefPubMed
Metadata
Title
Intellectual landscapes and emerging trends of non-steroidal mineralocorticoid receptor antagonists: a bibliometric and visual analysis
Authors
Lili Zhu
Ping Shi
Publication date
25-04-2024
Publisher
Springer Netherlands
Published in
International Urology and Nephrology
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-024-04059-9
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare